In the ICC classification, the same entity is defined as the myeloid neoplasm with two distinct TP53 mutations (MDS-TP53, MDS/AML-TP53), each with a variant allele frequency (VAF) of >10% or a single TP53 mutation with one of the three following criteria (1): 17p deletion on classical cytogenetics; or (2) VAF of >50%; or (3) copy-neutral LOH at the 17p TP53 locus (33). This evidence concerns the gene TP53 and myelodysplastic syndrome.